Exelixis (EXEL) Other financing activities (2010 - 2020)

Exelixis (EXEL) recorded quarterly Other financing activities of -$8000.0 in Q1 2020, up 33.33% quarter-over-quarter from -$12000.0 in Q3 2019.

Exelixis (EXEL) Other financing activities (2010 - 2020) Analysis & Trends

Exelixis' Other financing activities history runs 3 years deep, the most recent figure standing at -$8000.0 for Q1 2020.

In Q1 2020, Other financing activities changed N/A year-over-year to -$8000.0; the TTM figure through Oct 2020 stood at -$8000.0 (down 100.41% YoY), while the FY2020 annual figure was -$42000.0, down 223.08% from the prior year.
Other financing activities was -$8000.0 for Q1 2020 at Exelixis, up from -$12000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of -$8000.0 in Q1 2020 to a low of -$12000.0 in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Exelixis	13.71 Bn	12.93 Bn	590.86 Mn

Download Data